BioCryst sells European ORLADEYO rights to Neopharmed Gentili for up to $264M

BIOCRYST PHARMACEUTICALS INC

Neopharmed Gentili pays $250M upfront, up to $14M milestones; closing expected by early October 2025.
Proceeds to retire all $249M remaining term debt, eliminating ~$70M future interest payments.
BioCryst now expects ~$700M cash and no term debt by end 2027, a $400M increase from prior guidance.
Sale includes European team; BioCryst saves at least $50M in annual operating expenses.
European ORLADEYO revenues still count toward global royalty tiers for OMERS and >$550M cap.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.